Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Association between mitochondrial DNA variations and Alzheimer's disease in the ADNI cohort.

Lakatos A, Derbeneva O, Younes D, Keator D, Bakken T, Lvova M, Brandon M, Guffanti G, Reglodi D, Saykin A, Weiner M, Macciardi F, Schork N, Wallace DC, Potkin SG; Alzheimer's Disease Neuroimaging Initiative..

Neurobiol Aging. 2010 Aug;31(8):1355-63. doi: 10.1016/j.neurobiolaging.2010.04.031.

2.

No consistent evidence for association between mtDNA variants and Alzheimer disease.

Hudson G, Sims R, Harold D, Chapman J, Hollingworth P, Gerrish A, Russo G, Hamshere M, Moskvina V, Jones N, Thomas C, Stretton A, Holmans PA, O'Donovan MC, Owen MJ, Williams J, Chinnery PF; GERAD1 Consortium..

Neurology. 2012 Apr 3;78(14):1038-42. doi: 10.1212/WNL.0b013e31824e8f1d.

3.

Mitochondrial DNA haplogroup B5 confers genetic susceptibility to Alzheimer's disease in Han Chinese.

Bi R, Zhang W, Yu D, Li X, Wang HZ, Hu QX, Zhang C, Lu W, Ni J, Fang Y, Li T, Yao YG.

Neurobiol Aging. 2015 Mar;36(3):1604.e7-16. doi: 10.1016/j.neurobiolaging.2014.10.009.

PMID:
25457022
4.

Mitochondrial DNA variants in a Japanese population of patients with Alzheimer's disease.

Tanaka N, Goto Y, Akanuma J, Kato M, Kinoshita T, Yamashita F, Tanaka M, Asada T.

Mitochondrion. 2010 Jan;10(1):32-7. doi: 10.1016/j.mito.2009.08.008.

PMID:
19703591
5.

Mitochondrial haplogroup H and Alzheimer's disease--is there a connection?

Maruszak A, Canter JA, Styczyńska M, Zekanowski C, Barcikowska M.

Neurobiol Aging. 2009 Nov;30(11):1749-55. doi: 10.1016/j.neurobiolaging.2008.01.004.

PMID:
18308428
6.

Mitochondrial alterations, oxidative stress and neuroinflammation in Alzheimer's disease.

Verri M, Pastoris O, Dossena M, Aquilani R, Guerriero F, Cuzzoni G, Venturini L, Ricevuti G, Bongiorno AI.

Int J Immunopathol Pharmacol. 2012 Apr-Jun;25(2):345-53. Review.

PMID:
22697066
7.

Mitochondrial DNA haplogroups and APOE4 allele are non-independent variables in sporadic Alzheimer's disease.

Carrieri G, Bonafè M, De Luca M, Rose G, Varcasia O, Bruni A, Maletta R, Nacmias B, Sorbi S, Corsonello F, Feraco E, Andreev KF, Yashin AI, Franceschi C, De Benedictis G.

Hum Genet. 2001 Mar;108(3):194-8.

PMID:
11354629
8.

Mitochondria and vascular lesions as a central target for the development of Alzheimer's disease and Alzheimer disease-like pathology in transgenic mice.

Aliev G, Seyidova D, Lamb BT, Obrenovich ME, Siedlak SL, Vinters HV, Friedland RP, LaManna JC, Smith MA, Perry G.

Neurol Res. 2003 Sep;25(6):665-74.

PMID:
14503022
9.

Evidence for sub-haplogroup h5 of mitochondrial DNA as a risk factor for late onset Alzheimer's disease.

Santoro A, Balbi V, Balducci E, Pirazzini C, Rosini F, Tavano F, Achilli A, Siviero P, Minicuci N, Bellavista E, Mishto M, Salvioli S, Marchegiani F, Cardelli M, Olivieri F, Nacmias B, Chiamenti AM, Benussi L, Ghidoni R, Rose G, Gabelli C, Binetti G, Sorbi S, Crepaldi G, Passarino G, Torroni A, Franceschi C.

PLoS One. 2010 Aug 6;5(8):e12037. doi: 10.1371/journal.pone.0012037.

10.

Mitochondrial dysfunction and Alzheimer's disease.

Maruszak A, Żekanowski C.

Prog Neuropsychopharmacol Biol Psychiatry. 2011 Mar 30;35(2):320-30. doi: 10.1016/j.pnpbp.2010.07.004. Review.

PMID:
20624441
11.

Effect of EPHA1 genetic variation on cerebrospinal fluid and neuroimaging biomarkers in healthy, mild cognitive impairment and Alzheimer's disease cohorts.

Wang HF, Tan L, Hao XK, Jiang T, Tan MS, Liu Y, Zhang DQ, Yu JT; Alzheimer’s Disease Neuroimaging Initiative..

J Alzheimers Dis. 2015;44(1):115-23. doi: 10.3233/JAD-141488.

PMID:
25182741
12.

Using CSF biomarkers to replicate genetic associations in Alzheimer's disease.

Schott JM; ADNI Investigators..

Neurobiol Aging. 2012 Jul;33(7):1486.e9-15. doi: 10.1016/j.neurobiolaging.2011.02.008.

13.

The APOE4 allele shows opposite sex bias in microbleeds and Alzheimer's disease of humans and mice.

Cacciottolo M, Christensen A, Moser A, Liu J, Pike CJ, Smith C, LaDu MJ, Sullivan PM, Morgan TE, Dolzhenko E, Charidimou A, Wahlund LO, Wiberg MK, Shams S, Chiang GC; Alzheimer's Disease Neuroimaging Initiative., Finch CE.

Neurobiol Aging. 2016 Jan;37:47-57. doi: 10.1016/j.neurobiolaging.2015.10.010.

PMID:
26686669
14.

HMGCR is a genetic modifier for risk, age of onset and MCI conversion to Alzheimer's disease in a three cohorts study.

Leduc V, De Beaumont L, Théroux L, Dea D, Aisen P, Petersen RC; Alzheimer's Disease Neuroimaging Initiative., Dufour R, Poirier J.

Mol Psychiatry. 2015 Jul;20(7):867-73. doi: 10.1038/mp.2014.81.

15.

Mitochondrial defects and oxidative stress in Alzheimer disease and Parkinson disease.

Yan MH, Wang X, Zhu X.

Free Radic Biol Med. 2013 Sep;62:90-101. doi: 10.1016/j.freeradbiomed.2012.11.014.

17.

Mitochondria, mitochondrial DNA and Alzheimer's disease. What comes first?

Mancuso M, Orsucci D, Siciliano G, Murri L.

Curr Alzheimer Res. 2008 Oct;5(5):457-68.

PMID:
18855587
18.

Neuroimaging biomarkers for Alzheimer's disease in asymptomatic APOE4 carriers.

Chételat G, Fouquet M.

Rev Neurol (Paris). 2013 Oct;169(10):729-36. doi: 10.1016/j.neurol.2013.07.025. Review.

PMID:
24016463
19.

Analysis of European mitochondrial haplogroups with Alzheimer disease risk.

van der Walt JM, Dementieva YA, Martin ER, Scott WK, Nicodemus KK, Kroner CC, Welsh-Bohmer KA, Saunders AM, Roses AD, Small GW, Schmechel DE, Murali Doraiswamy P, Gilbert JR, Haines JL, Vance JM, Pericak-Vance MA.

Neurosci Lett. 2004 Jul 15;365(1):28-32.

PMID:
15234467
20.

Impact of SORL1 single nucleotide polymorphisms on Alzheimer's disease cerebrospinal fluid markers.

Alexopoulos P, Guo LH, Kratzer M, Westerteicher C, Kurz A, Perneczky R.

Dement Geriatr Cogn Disord. 2011;32(3):164-70. doi: 10.1159/000332017.

Items per page

Supplemental Content

Support Center